Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChloraPrep is a topical antiseptic solution containing 2% chlorhexidine gluconate (CHG) and 70% isopropyl alcohol (IPA). It is widely used for skin preparation prior to surgical procedures or vascular catheterization to reduce the risk of infections. The mechanism of action involves the rapid, broad-spectrum bactericidal activity of isopropyl alcohol through protein denaturation, combined with the persistent antimicrobial effect of chlorhexidine gluconate, which disrupts bacterial cell membranes and walls. In the CLEAN 2 trial, sponsored by Poitiers University Hospital, this specific formulation was evaluated for its efficacy in preventing surgical site infections (SSIs) in patients undergoing major cardiac surgery via sternotomy. The trial results indicated that the CHG-IPA solution was not superior to povidone-iodine-alcohol in reducing reoperation or SSI rates in this specific surgical context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ChloraPrep.